DaVita (DVA) Expands Humana Partnership, Is The Stock Still Undervalued?

DaVita (DVA) has entered a new value based care agreement with Humana to manage Medicare Advantage members with earlier stage chronic kidney disease, extending their existing partnership beyond end stage care.

Against this backdrop, DaVita’s share price has eased in the short term, with a 30 day share price return of down 26.64%. However, the year to date share price return is 53.82% and the 3 year total shareholder return is 82.25%, suggesting that longer term momentum remains stronger than the recent pullback.

Compare how DaVita's kidney care focus stacks up against other healthcare stocks with strong fundamentals by scanning the list of solid balance sheet and fundamentals (53 results) that are already positioned for disciplined growth.

DaVita now combines a focused kidney care business with a share price that has surged over the past year, yet pulled back sharply in the last month. Does that recent drop leave the stock fairly priced today?

Most Popular Narrative: 19.4% Undervalued

The most followed DaVita narrative estimates a fair value of about $218 per share, compared with the last close at $176.14, which points to a sizeable valuation gap for investors to assess.

Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth.

Read the complete narrative.

Want to see what underpins that valuation gap for DaVita? The narrative leans heavily on steady revenue growth, firmer margins and a future earnings multiple that undercuts many healthcare peers. Curious how those moving parts combine into one fair value number?

Result: Fair Value of $218.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to watch for risks such as reimbursement rates that lag rising costs and treatment volumes that remain below DaVita’s long term targets.

Find out about the key risks to this DaVita narrative.

Next Steps

With DaVita facing both concerns and optimism, it makes sense to move quickly and review the evidence yourself so you can decide where you stand using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond DaVita?

If you like the DaVita story, do not stop there. Use focused stock lists to quickly spot other opportunities that fit the kind of portfolio you want to build.

• Target potential mispricing by scanning companies that screen as high quality yet overlooked through the 19 high quality undiscovered gems.
• Prioritise resilience and sleep easier at night by reviewing stocks with stronger balance sheets using this curated list of solid balance sheet and fundamentals (53 results).
• Strengthen your income stream by checking out companies that combine higher yields with sturdier fundamentals through the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.